Sarepta Therapeutics Shares Face Persistent Analyst Doubt Despite Upward Earnings Revision
Published on 09/15/2025 at 06:00 | Redaktion boerse-global.deSarepta Therapeutics shares closed Friday’s trading session down 2.9 percent at $17.39, a decline that occurred despite a positive earnings forecast adjustment from Leerink Partners.
While Leerink Partners upgraded its third-quarter 2025 EPS estimate from -$1.08 to -$0.70, the firm maintained its “Hold” rating on the biopharmaceutical company. The broader analyst consensus, comprising seven research firms, also showed modest improvement, moving from -$0.37 to -$0.31 per share.
The overall sentiment toward Sarepta remains cautious. Among the 29 analyst firms covering the stock, recommendations include eight “Buy” ratings, fifteen “Hold” positions, and six “Sell” advisories. Price targets reflect significant divergence, ranging from $30.50 to $68.59 per share.
Regulatory Environment and Strategic Shifts
Significant regulatory developments in July 2025 created substantial uncertainty for... Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
